Christina Mattina

Abstracts presented at the 2022 European Hematology Association Congress demonstrate superior health-related quality of life (HRQOL) outcomes among patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) taking zanubrutinib.

In abstracts featured at the 2022 European Hematology Association Congress, investigators detailed long-term results of the ASPEN phase 3 trial and an expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia (WM).

An education session at the 2022 European Hematology Association Congress featured updates on using genetic and immune characteristics to select the optimal treatment pathway in chronic lymphocytic leukemia (CLL).

The 2022 European Hematology Association (EHA) Congress will be the group’s first hybrid meeting, in which investigators will convene both virtually and in Vienna, Austria, from June 9-12, 2022, to present cutting-edge findings in the realm of oncology and hematology.

Abstracts presented at Digestive Disease Week 2022 showed that RBX2660, an investigational microbiota-based drug, was more likely to reduce the recurrence of Clostridioides difficile infection (CDI) compared with placebo.

During a State-of-the-Art Lecture at Digestive Disease Week 2022, Jessica L. Mellinger, MD, MSc, explained how the COVID-19 pandemic has driven increases in rates of alcohol use and associated liver disease, as well as what can be done at the clinic, societal, and policy levels to address these trends.

Evidence shows that weight loss achieved through bariatric and endoscopic surgery can help treat and reverse nonalcoholic fatty liver disease (NAFLD), but optimal procedure selection and timing vary by patient factors, according to speakers at Digestive Disease Week 2022.

A pair of posters presented at Digestive Disease Week 2022 showed the efficacy of an investigational biotherapeutic in preventing Clostridioides difficile infection recurrence and restoring the microbiome.

Speakers at Digestive Disease Week 2022 presented research on how health disparities and socioeconomic factors can contribute to changes in the gut microbiome that have implications for cancer risk, immune health, and overall well-being.

As artificial intelligence (AI) technology in the gastrointestinal field continues to advance, speakers at Digestive Disease Week 2022 discussed how these tools can be put into practice to improve efficiency, reduce physician burnout, and reap cost savings.

Digestive Disease Week (DDW) 2022, held virtually and in San Diego, California, from May 21 to 24, will feature research and presentations exploring new ways to prevent and treat digestive diseases.

The Senate voted 50-46 to confirm Robert Califf, MD, as commissioner of the FDA, which has been without a permanent leader for more than a year.

This year’s most-read articles on HIV explored vaccine hesitancy, medication acceptance, cardiac health, and more.

In a year that saw conferences return to in-person venues, the most popular conference coverage on AJMC.com included articles and videos from meetings on oncology, cardiology, dermatology, and more.

This year’s most-read articles on Fabry disease touched on advancements in therapy, health risks of the disease, and keys to improved diagnosis.

In 2021, the articles published in the peer-reviewed The American Journal of Managed Care® (AJMC®) explored responses to the COVID-19 pandemic, the potential of health policy reforms, the importance of population health, and much more.

This year’s most-read articles on Medicare covered topics including accountable care organizations, value-based payment, and star ratings.

In a 7 to 2 decision, the Supreme Court ruled Thursday that the Affordable Care Act (ACA) will stand, as plaintiffs seeking to declare the law unconstitutional did not have standing.

There are a number of new biologic options for treating psoriasis, but undertreatment is still a concern, and more long-term data are needed, according to Junko Takeshita, MD, PhD, MSCE, at the National Association of Managed Care Physicians Virtual Spring Managed Care Forum.

Now that investigators have a better understanding of the biological mechanisms of migraine, new treatment and prevention options are making their way to patients and fueling an exciting time for the field, according to a presenter at the National Association of Managed Care Physicians Virtual Spring Managed Care Forum.

With the costs of biologic drugs increasing, biosimilars have emerged as an attractive option for containing costs and expanding access to treatment. However, some barriers to wider uptake still need to be addressed, according to a presentation at the National Association of Managed Care Physicians Virtual Spring Managed Care Forum.

Because health literacy can have different meanings for patients with different diseases, this review aimed to crystalize a definition in patients with multiple sclerosis (MS) and emphasize its importance in care planning.

The coronavirus disease 2019 (COVID-19) pandemic dominated headlines for much of 2020, and most of the top 5 multiple sclerosis articles of this year discussed the effects of COVID-19 on patients with this disease. Others touched on physician and patient assessments of relapse and potential new treatments for neural damage.

In 2020, articles published in The American Journal of Accountable Care® (AJAC) explored drivers of success in accountable care organizations, responses to payment reform efforts, and more.

In 2020, the peer-reviewed articles published in the pages of The American Journal of Managed Care® (AJMC®) that drew the most readers were largely, but not entirely, related to the coronavirus disease 2019 crisis.

This year, the most popular articles and interviews related to the role of inflammation in asthma and other conditions touched on the mechanisms of inflammation, patterns of inhaler use, and the real-world impacts of the monoclonal antibody dupilumab.

In a pair of sessions at the Quality Cancer Care Alliance Virtual Fall Leadership Summit, speakers discussed the promise of precision medicine for not only informing individuals’ cancer treatment decisions but also identifying individuals at high risk before disease develops.

In her presentation, Aimee Tharaldson, PhD, senior clinical pharmacist of emerging therapeutics at Express Scripts, discussed the upcoming pipeline of specialty drug approvals and their potential impact on the market.